Applied Therapeutics, Inc. Investors are being notified of a pending class action and are being asked to contact the BFA Act before the February 18 deadline By Investing.com

NEW YORK, NY–( The News File Corp. – Jan 12, 2025 ) – A leading securities law firm. Bleichmar Fonti & Auld LLP By Applied Therapeutics, Inc. (NASDAQ: NASDAQ: ) and announced that some of the company’s top executives have been charged with violating federal securities laws.

If you are investing in Applied Therapeutics, you are encouraged to visit for more information https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.

Investors have until February 18, 2025 to request that the court be appointed to preside over the case. The complaint represents investors in Applied Therapeutics’ securities in claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The case is pending in the U.S. District Court for the Southern District of New York and a brief has been filed. Alexander v. Applied Therapeutics, Inc., inter alia.No. 24-cv-09715.

What is the charge about?

Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing new drugs against proven molecular targets in rare diseases. The company’s lead candidate, govorestat, is a central nervous system-penetrating aldose reductase inhibitor for the treatment of rare metabolic diseases of the CNS, including galactosemia.

In the relevant period, the company’s new drug applications for Govorestat regulators were “supported by a rapid and sustained reduction in galactitol, which, along with a safety profile, resulted in significant benefits in pediatric patients.” Applied Therapeutics told investors that the tests were “conducted appropriately” and that the company “felt good about the quality of the data,” that it “took really extensive steps” and that it was “actually videotaped” and had “head coaches” review it all. Performance of the 10-meter walk test – the primary endpoint of the company’s phase III INSPIRE study for Govorest.

When the truth is revealed, the stock goes down

On November 27, 2024, Applied Therapeutics issued a press release announcing that the FDA had issued a full response letter to the NDA for govorestat. The full response letter states that the FDA has completed its review of the application and determined that it was unable to approve the NDA due to “deficiencies in the clinical application.”

This news sent Applied Therapeutics’ stock price down more than 80% over several trading days, from a closing price of $10.21 per share on November 26, 2024 to a closing price of $1.75 per share on December 2, 2024.

Then, on December 2, 2024, Applied Therapeutics said it received a warning letter from the FDA about “issues related to electronic data capture” and “a dose error encountered during the dose-escalation phase of the study at slightly lower than planned doses in a limited number of patients (.).”

The news caused Applied Therapeutics’ stock price to drop more than 26% over several trading days, from a closing price of $1.75 per share on December 2, 2024 to a closing price of $1.29 per share on December 5, 2024.

Click here for more information: https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.

What can you do?

If you invest in Applied Therapeutics, you may have legal options and are encouraged to provide your information to the company.

All representations are on a contingency fee basis, at no cost to you. Shareholders are not responsible for any court costs or court costs. The firm will seek court approval for any potential fees and expenses.

Enter your information by visiting:

https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. In the year Named among the Top 5 Plaintiff Law Firms in 2023 by ISS SCAS, Lawyers by Law360 and SuperLawyers by Thompson Reuters. Among recent notable accomplishments, BFA was valued at over $900 million from Tesla (NASDAQ:) Inc. board of directors, as well as $420 million from Teva Pharmaceuticals (NYSE: ) Ind. Ltd. have got.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc

Notice of attorney. Past results do not guarantee future results.

To view the source of this press release, please visit https://www.newsfilecorp.com/release/236593.